South Korea · Delayed Price · Currency is KRW ADBiotech Statistics
Total Valuation
ADBiotech has a market cap or net worth of KRW 46.15 billion. The enterprise value is 52.91 billion.
| Market Cap | 46.15B |
| Enterprise Value | 52.91B |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADBiotech has 19.68 million shares outstanding. The number of shares has increased by 55.08% in one year.
| Current Share Class | 19.68M |
| Shares Outstanding | 19.68M |
| Shares Change (YoY) | +55.08% |
| Shares Change (QoQ) | +33.42% |
| Owned by Insiders (%) | 13.65% |
| Owned by Institutions (%) | 10.89% |
| Float | 12.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.69 |
| PB Ratio | 3.23 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 60.21 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.35 |
| EV / Sales | 4.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.51 |
Financial Position
The company has a current ratio of 0.49, with a Debt / Equity ratio of 0.94.
| Current Ratio | 0.49 |
| Quick Ratio | 0.28 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.89 |
| Interest Coverage | -1.92 |
Financial Efficiency
Return on equity (ROE) is -80.20% and return on invested capital (ROIC) is -20.37%.
| Return on Equity (ROE) | -80.20% |
| Return on Assets (ROA) | -8.03% |
| Return on Invested Capital (ROIC) | -20.37% |
| Return on Capital Employed (ROCE) | -24.83% |
| Weighted Average Cost of Capital (WACC) | 7.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.37 |
| Inventory Turnover | 3.47 |
Taxes
| Income Tax | -173.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.55% in the last 52 weeks. The beta is 0.18, so ADBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | +30.55% |
| 50-Day Moving Average | 2,718.10 |
| 200-Day Moving Average | 2,706.54 |
| Relative Strength Index (RSI) | 40.79 |
| Average Volume (20 Days) | 162,074 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ADBiotech had revenue of KRW 12.51 billion and -8.33 billion in losses. Loss per share was -579.01.
| Revenue | 12.51B |
| Gross Profit | 4.84B |
| Operating Income | -4.36B |
| Pretax Income | -8.30B |
| Net Income | -8.33B |
| EBITDA | -3.44B |
| EBIT | -4.36B |
| Loss Per Share | -579.01 |
Balance Sheet
The company has 5.57 billion in cash and 13.40 billion in debt, with a net cash position of -7.83 billion or -397.62 per share.
| Cash & Cash Equivalents | 5.57B |
| Total Debt | 13.40B |
| Net Cash | -7.83B |
| Net Cash Per Share | -397.62 |
| Equity (Book Value) | 14.30B |
| Book Value Per Share | 800.16 |
| Working Capital | -12.77B |
Cash Flow
In the last 12 months, operating cash flow was 766.49 million and capital expenditures -15.84 billion, giving a free cash flow of -15.08 billion.
| Operating Cash Flow | 766.49M |
| Capital Expenditures | -15.84B |
| Depreciation & Amortization | 923.76M |
| Net Borrowing | 9.40B |
| Free Cash Flow | -15.08B |
| FCF Per Share | -766.15 |
Margins
Gross margin is 38.69%, with operating and profit margins of -34.86% and -66.58%.
| Gross Margin | 38.69% |
| Operating Margin | -34.86% |
| Pretax Margin | -66.36% |
| Profit Margin | -66.58% |
| EBITDA Margin | -27.48% |
| EBIT Margin | -34.86% |
| FCF Margin | n/a |
Dividends & Yields
ADBiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -55.08% |
| Shareholder Yield | -55.08% |
| Earnings Yield | -18.05% |
| FCF Yield | -32.67% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.
| Last Split Date | May 26, 2021 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
ADBiotech has an Altman Z-Score of -0.73 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.73 |
| Piotroski F-Score | 4 |